Becton, Dickinson and Company (NYSE:BDX) Issues FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 12.520-12.720 for the period, compared to the consensus EPS estimate of 12.490. The company issued revenue guidance of -.

Analyst Ratings Changes

A number of research firms have weighed in on BDX. TD Cowen reduced their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Friday, April 10th. They issued a “neutral” rating and a $167.00 price objective on the stock. Evercore boosted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday. Piper Sandler reduced their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Seven analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $184.71.

Becton, Dickinson and Company Trading Down 2.6%

BDX traded down $4.02 during trading on Friday, reaching $149.24. 4,481,804 shares of the stock traded hands, compared to its average volume of 3,155,492. The company has a quick ratio of 0.58, a current ratio of 0.94 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $42.49 billion, a PE ratio of 37.78, a P/E/G ratio of 10.90 and a beta of 0.22. The stock’s 50-day moving average is $158.49 and its 200 day moving average is $181.08. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.32%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.56 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio is 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 1,102 shares of company stock worth $198,909 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Evercore raised its price target on BDX from $180 to $190, signaling continued confidence in the company’s outlook. Evercore target increase
• Positive Sentiment: Wells Fargo lifted its price target to $161 from $157, suggesting modest upside from current levels. Wells Fargo target increase
• Positive Sentiment: The company’s earnings beat, revenue beat, and higher profit guidance are supporting the stock’s rebound after the report. BD second-quarter fiscal 2026 financial results
• Neutral Sentiment: BD also appointed Vitor Roque as chief financial officer, a management change that is not clearly positive or negative for the stock. BD appoints Vitor Roque CFO
• Neutral Sentiment: Stifel lowered its price target to $175 from $215, which is still above the current share price but reflects a more cautious view. Stifel target cut

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cambient Family Office LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $217,000. Compound Planning Inc. boosted its position in shares of Becton, Dickinson and Company by 72.9% during the 4th quarter. Compound Planning Inc. now owns 2,887 shares of the medical instruments supplier’s stock worth $560,000 after purchasing an additional 1,217 shares in the last quarter. Invesco Ltd. boosted its position in shares of Becton, Dickinson and Company by 48.5% during the 4th quarter. Invesco Ltd. now owns 3,790,490 shares of the medical instruments supplier’s stock worth $735,620,000 after purchasing an additional 1,237,507 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in shares of Becton, Dickinson and Company by 22.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 28,140 shares of the medical instruments supplier’s stock worth $5,461,000 after purchasing an additional 5,106 shares in the last quarter. Finally, Andrews Advisory Associates LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $253,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.